reviewed april 2026|next review october 2026|88 physicians psi has verified|5012 published studies
Enclomiphene
Enclomiphene is the trans-isomer of clomiphene citrate (Clomid), a selective estrogen receptor modulator (SERM) that raises testosterone by blocking hypothalamic estrogen feedback, with completed Phase III trials showing testosterone normalization while preserving spermatogenesis.
Evidence landscape: 5012 published studies
5,012 published items. 41 human studies and 114 animal studies.
- 41 Human
- 114 Animal
- 45 Reviews
- 4812 Other research
Not FDA-approved despite completed Phase III trials with positive data. The path to approval remains unclear. Clomiphene citrate (Clomid), which contains both enclomiphene and zuclomiphene isomers, is FDA-approved for female ovulation induction and used in men for purposes the FDA has not formally approved.
Available through specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient. Not available as an FDA-approved pharmaceutical product.
Selective estrogen receptor modulator (SERM). Raises testosterone by blocking hypothalamic estrogen feedback, preserving spermatogenesis unlike exogenous testosterone replacement.
PSI Assessment
The concept addresses a specific clinical gap: men who need testosterone but want to preserve fertility. Enclomiphene is the active trans-isomer of clomiphene citrate (Clomid), isolated to block estrogen receptors in the hypothalamus without the mixed agonist/antagonist effects of the parent drug. Phase III trials demonstrated testosterone normalization in men with secondary hypogonadism while maintaining sperm production, something exogenous testosterone replacement cannot do. Despite positive Phase III data, FDA approval has not been granted, and the compound is available through specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient.
Raises testosterone while preserving fertility. Phase III data is positive. FDA approval has not been granted despite completed trials.
The mechanism is selective estrogen receptor antagonism at the hypothalamus and pituitary. Blocking estrogen feedback increases GnRH (gonadotropin-releasing hormone) pulse frequency, which elevates LH (luteinizing hormone) and FSH (follicle-stimulating hormone) secretion. This stimulates the body's own testosterone production while maintaining spermatogenesis. Unlike exogenous testosterone, enclomiphene keeps the HPG (hypothalamic-pituitary-gonadal) axis active.
What the evidence supports
Phase III trials demonstrate testosterone normalization in secondary hypogonadism with preserved spermatogenesis. The SERM mechanism is well-characterized: estrogen receptor antagonism at the hypothalamus increases LH and FSH, stimulating the body's own testosterone production. Enclomiphene isolates the anti-estrogenic trans-isomer without the estrogenic zuclomiphene component. Multiple human trials confirm the hormonal profile.
What is not yet established
Why FDA approval has not been granted despite positive Phase III data. Whether enclomiphene produces equivalent clinical benefits to testosterone replacement for symptoms beyond hormone levels (energy, body composition, libido). Long-term safety beyond trial durations. Whether enclomiphene is meaningfully superior to clomiphene citrate (Clomid), which is already available.
Research Evidence
The findings below cover what Phase III data has established and where the remaining questions about clinical outcomes and regulatory status stand.
Evidence by condition
Evidence dimensions across enclomiphene's investigated applications. Secondary hypogonadism and fertility preservation have Phase III human data. Testosterone optimization has observational data from use the FDA has not formally approved.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Secondary Hypogonadism | ||||
| Fertility Preservation | ||||
| Testosterone Optimization |
Phase III trials (ZA-304 and ZA-305) demonstrated testosterone normalization in men with secondary hypogonadism while preserving or improving spermatogenesis. Mean testosterone increased from below 300 ng/dL to the normal range.
These are completed Phase III trials with positive data. The regulatory path forward is unclear despite these results.
Enclomiphene preserves spermatogenesis during treatment, a key advantage over testosterone replacement therapy which suppresses sperm production. This makes it particularly relevant for men of reproductive age.
Direct fertility outcome data (conception rates) has not been studied in controlled trials. The fertility preservation is inferred from maintained sperm parameters.
Enclomiphene isolates the trans-isomer from clomiphene citrate, removing the estrogenic zuclomiphene component. This may reduce estrogen-related side effects compared to the mixed isomer parent drug.
Whether enclomiphene is clinically superior to clomiphene citrate (Clomid), which is already widely used for purposes the FDA has not formally approved, is not established in head-to-head comparison.
41 Human|114 Animal|45 Reviews
View all 5012 indexed studiesHow Enclomiphene Works
Enclomiphene is the trans-isomer of clomiphene citrate, acting as a selective estrogen receptor antagonist at the hypothalamus and pituitary.
When the brain detects enough estrogen, it tells the pituitary to stop producing LH and FSH, the hormones that drive testosterone production. Enclomiphene blocks this estrogen feedback signal, causing the pituitary to respond by producing more LH, which tells the testes to produce more testosterone. All while keeping natural production running.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Enclomiphene is the trans-isomer of clomiphene citrate, acting as a selective estrogen receptor antagonist at the hypothalamus and pituitary. By blocking estrogen negative feedback, it increases GnRH pulse frequency, elevating LH and FSH secretion. This stimulates the body's own testosterone production while maintaining spermatogenesis.
What is Enclomiphene being studied for?
Researchers are studying Enclomiphene across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Enclomiphene overall. This means a compound can have human studies for one condition but only animal data for another.
Secondary Hypogonadism
·Human TrialsPhase III trials showed enclomiphene normalized testosterone levels in men with secondary hypogonadism while maintaining sperm counts, a key advantage over testosterone replacement.
Limitations: FDA approval has not been granted despite positive Phase III data. Long-term outcomes data beyond trial durations is limited.
Fertility Preservation
·Human TrialsUnlike testosterone replacement which suppresses sperm production, enclomiphene maintains or improves spermatogenesis by keeping the HPG axis active. This is its primary advantage for men of reproductive age.
Limitations: Direct fertility outcome data (conception rates) has not been studied in controlled trials.
Testosterone Optimization
·Animal StudiesUsed through specialty pharmacies as a non-injectable testosterone booster. Oral dosing is a practical advantage over injection-based testosterone replacement.
Limitations: Whether the testosterone increase produces the same clinical outcomes as testosterone replacement (energy, body composition, libido) is not established in head-to-head trials.
Safety and Regulatory Status
FDA Status: Not FDA-approved despite completed Phase III trials. Clomiphene citrate (Clomid) is FDA-approved for female ovulation induction and used in men for purposes the FDA has not formally approved.
Availability: Available through specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient. Not available as an FDA-approved pharmaceutical product.
Class context: Well-tolerated in clinical trials. Common side effects include headache, hot flashes, and nausea, similar to clomiphene citrate but potentially fewer mood-related side effects since it lacks the estrogenic zuclomiphene isomer.
Enclomiphene has been well tolerated in clinical trials. Common side effects include headache, hot flashes, and nausea, similar to clomiphene citrate but potentially fewer mood-related side effects (since it lacks the estrogenic zuclomiphene isomer). Enclomiphene is not FDA-approved but is available through specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient.
Questions and Comparisons
Questions the evidence raises for a Enclomiphene discussion.
Comparison and Related Research
Enclomiphene is most often compared with other approaches to testosterone optimization that preserve the HPG axis.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Randomized Phase 2 trial comparing enclomiphene citrate to topical testosterone gel in men with secondary hypogonadism. While both treatments raised serum testosterone, enclomiphene maintained or improved sperm counts, whereas topical testosterone suppressed sperm production. This distinction is central to the clinical interest in enclomiphene as an alternative to testosterone replacement therapy.Wiehle RD et al., 2014 in Fertil Steril. View on PubMed
- 2.Study comparing enclomiphene to topical testosterone in obese men with secondary hypogonadism. Enclomiphene restored testosterone levels to the normal range while preserving spermatogenesis. The results reinforced the concept that stimulating the hypothalamic-pituitary-gonadal axis through selective estrogen receptor modulation can correct low testosterone without the fertility suppression caused by exogenous testosterone.Kim ED et al., 2016 in BJU Int. View on PubMed
- 3.Dose-ranging study that established the efficacy profile of enclomiphene at 12.5 mg and 25 mg daily doses compared to testosterone gel. Both enclomiphene doses raised testosterone into the normal range, and sperm concentrations were maintained or increased. The study confirmed that oral enclomiphene could provide an alternative to injectable or topical testosterone for men who want to preserve fertility.Kaminetsky J et al., 2013 in J Sex Med. View on PubMed
- 4.Comprehensive review of enclomiphene citrate's pharmacology and clinical data for secondary male hypogonadism. The paper discusses how enclomiphene, the trans-isomer of clomiphene, selectively blocks estrogen receptors in the hypothalamus, releasing the negative feedback that suppresses LH and FSH. This mechanism restores endogenous testosterone production through the natural hormonal axis rather than bypassing it with exogenous hormone.Rodriguez KM et al., 2016 in Expert Opin Pharmacother. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.